|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGO2 |
Gene summary for AGO2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGO2 | Gene ID | 27161 |
| Gene name | argonaute RISC catalytic component 2 | |
| Gene Alias | CASC7 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9UKV8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27161 | AGO2 | LZE4T | Human | Esophagus | ESCC | 1.10e-09 | 1.37e-02 | 0.0811 |
| 27161 | AGO2 | LZE7T | Human | Esophagus | ESCC | 1.50e-05 | 3.31e-01 | 0.0667 |
| 27161 | AGO2 | LZE8T | Human | Esophagus | ESCC | 6.48e-07 | 1.58e-01 | 0.067 |
| 27161 | AGO2 | LZE20T | Human | Esophagus | ESCC | 1.38e-08 | 1.23e-01 | 0.0662 |
| 27161 | AGO2 | LZE24T | Human | Esophagus | ESCC | 6.55e-07 | 2.37e-01 | 0.0596 |
| 27161 | AGO2 | LZE6T | Human | Esophagus | ESCC | 6.44e-03 | -3.04e-02 | 0.0845 |
| 27161 | AGO2 | P1T-E | Human | Esophagus | ESCC | 1.00e-03 | 2.29e-01 | 0.0875 |
| 27161 | AGO2 | P2T-E | Human | Esophagus | ESCC | 2.13e-22 | 4.05e-01 | 0.1177 |
| 27161 | AGO2 | P4T-E | Human | Esophagus | ESCC | 1.15e-12 | 4.25e-01 | 0.1323 |
| 27161 | AGO2 | P5T-E | Human | Esophagus | ESCC | 3.30e-10 | 1.93e-01 | 0.1327 |
| 27161 | AGO2 | P8T-E | Human | Esophagus | ESCC | 3.33e-14 | 2.96e-01 | 0.0889 |
| 27161 | AGO2 | P9T-E | Human | Esophagus | ESCC | 1.14e-15 | 2.87e-01 | 0.1131 |
| 27161 | AGO2 | P10T-E | Human | Esophagus | ESCC | 7.01e-30 | 5.73e-01 | 0.116 |
| 27161 | AGO2 | P11T-E | Human | Esophagus | ESCC | 3.57e-07 | 2.84e-01 | 0.1426 |
| 27161 | AGO2 | P12T-E | Human | Esophagus | ESCC | 5.99e-22 | 5.36e-01 | 0.1122 |
| 27161 | AGO2 | P15T-E | Human | Esophagus | ESCC | 8.69e-26 | 5.75e-01 | 0.1149 |
| 27161 | AGO2 | P16T-E | Human | Esophagus | ESCC | 4.93e-25 | 6.66e-01 | 0.1153 |
| 27161 | AGO2 | P17T-E | Human | Esophagus | ESCC | 1.94e-05 | 2.78e-01 | 0.1278 |
| 27161 | AGO2 | P20T-E | Human | Esophagus | ESCC | 9.31e-17 | 2.60e-01 | 0.1124 |
| 27161 | AGO2 | P21T-E | Human | Esophagus | ESCC | 6.28e-27 | 4.72e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:000095618 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process | 88/8552 | 112/18723 | 9.41e-13 | 4.14e-11 | 88 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGO2 | SNV | Missense_Mutation | c.1378N>T | p.Arg460Cys | p.R460C | Q9UKV8 | protein_coding | deleterious(0) | possibly_damaging(0.674) | TCGA-A2-A0CV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| AGO2 | SNV | Missense_Mutation | c.1103C>G | p.Thr368Ser | p.T368S | Q9UKV8 | protein_coding | tolerated(0.1) | possibly_damaging(0.626) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| AGO2 | SNV | Missense_Mutation | c.614N>T | p.Ser205Phe | p.S205F | Q9UKV8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| AGO2 | SNV | Missense_Mutation | rs866981753 | c.2140N>T | p.Arg714Trp | p.R714W | Q9UKV8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| AGO2 | SNV | Missense_Mutation | c.2149T>A | p.Cys717Ser | p.C717S | Q9UKV8 | protein_coding | tolerated(0.13) | benign(0.271) | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| AGO2 | SNV | Missense_Mutation | novel | c.1981N>A | p.Pro661Thr | p.P661T | Q9UKV8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| AGO2 | SNV | Missense_Mutation | c.931N>C | p.Tyr311His | p.Y311H | Q9UKV8 | protein_coding | deleterious(0.02) | possibly_damaging(0.857) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| AGO2 | SNV | Missense_Mutation | novel | c.2165N>T | p.Glu722Val | p.E722V | Q9UKV8 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| AGO2 | SNV | Missense_Mutation | novel | c.1940N>A | p.Arg647His | p.R647H | Q9UKV8 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| AGO2 | SNV | Missense_Mutation | c.1250N>A | p.Ser417Tyr | p.S417Y | Q9UKV8 | protein_coding | tolerated(0.09) | benign(0.308) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |